1 March 2024 - The March 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The March issue of the Schedule includes a only few new/revised listings of note:

• Abiraterone acetate and methylprednisolone (Yonsa Mpred) - new indication
• Dapagliflozin propanediol monohydrate (Forxiga) - new indication
• Ibrutinib (Imbruvica) - new formulation
• Nirmatrelvir and ritonavir (Paxlovid) - restriction change
• Nusinersen sodium (Spinraza) - restriction change

Read Summary of PBS changes